Bio-Techne Corporation (TECH)

Bio-Techne's stock (TECH) experienced fluctuations in the past six months. The share price on December 31, 2025, was $58.81, a 17.73% decline from $71.48 on January 2, 2025, with a 52-week range between $46.01 and $79.28. Q1 2026 earnings reported a 1% organic revenue decline due to clinical stage programs and biotech funding softness, but saw robust demand from large pharmaceutical companies and stabilization in U.S. academic markets, with growth in China. Q2 CY2025 results exceeded market revenue expectations, with sales up 3.5% year-on-year to $317 million. Analyst sentiment is a "Moderate Buy," although Evercore ISI recently downgraded Bio-Techne to "In Line."

Demand for Bio-Techne's products and services is influenced by research funding levels, diagnostics adoption, and biotech innovation cycles. Demand can experience "lumpiness" due to the nature of late-stage clinical programs and is impacted by softness in biotech funding. In China, the revenue mix has temporarily shifted towards consumables due to a challenging economic environment, with stimulus-related tender activity expected to contribute to modest positive growth in Q3 FY25.

Bio-Techne Corp. is a global life sciences company focused on biotechnology reagents, instruments, and services for research, diagnostic, and bioprocessing markets, operating in the Health Care sector. Its business is segmented into Protein Sciences (75% of revenue), focusing on purified proteins, reagents, and analytical instruments, and Diagnostics and Spatial Biology (25% of revenue), providing diagnostic reagents, molecular diagnostics, and spatial biology products. The company's portfolio includes ELISA kits, ELISpot kits, enzymes, Luminex assays, GMP products, nucleic acid probes and kits, single-cell analysis solutions, and automated protein analysis systems, serving scientific disciplines like immunology, neuroscience, cancer research, and stem cell biology. Key brands include ACD, Asuragen, Lunaphore, Novus Biologicals, ProteinSimple, R&D Systems, and Tocris Bioscience.

Bio-Techne is headquartered in Minneapolis, Minnesota, USA, and employs over 3,000 people across 34 locations worldwide. The company has a global distribution network with a significant international presence. North America accounts for approximately 55% of its revenue. Europe is another key region, with subsidiaries in multiple countries. China represents about 9% of Bio-Techne's global revenue and has a wholly-owned subsidiary in Shanghai, with a sales subsidiary in Hong Kong. The company also serves customers in Africa and the Middle East.

Bio-Techne is recognized as a global leader in life sciences, committed to advancing scientific discovery and improving human health through high-quality reagents, instruments, and services. The company released its 2025 Corporate Sustainability Report, highlighting progress on climate, innovation, and culture, including an estimated 40% reduction in Scope 1 and 2 emissions. A licensing agreement for AI-designed NovoBody™ Duo molecules from Monod Bio is expected to strengthen Bio-Techne's leadership in AI-enabled protein innovation, positioning the company as a leader in the precision medicine megatrend.

Bio-Techne's shareholder base is predominantly institutional, with institutional owners holding between 97.61% and 98.9% of the shares, while individual insiders hold between 1.05% and 2.50%. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., Morgan Stanley, State Street Corp, Wellington Management Group Llp, Geode Capital Management, Llc, Invesco Ltd., T. Rowe Price Associates, Neuberger Berman, and Maverick Capital. Recent insider trading activity shows some selling by officers and directors.